JP7505912B2 - オートファジー活性化剤 - Google Patents
オートファジー活性化剤 Download PDFInfo
- Publication number
- JP7505912B2 JP7505912B2 JP2020080581A JP2020080581A JP7505912B2 JP 7505912 B2 JP7505912 B2 JP 7505912B2 JP 2020080581 A JP2020080581 A JP 2020080581A JP 2020080581 A JP2020080581 A JP 2020080581A JP 7505912 B2 JP7505912 B2 JP 7505912B2
- Authority
- JP
- Japan
- Prior art keywords
- active ingredient
- autophagy
- tocopherol
- diseases
- salts
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 230000004900 autophagic degradation Effects 0.000 title claims description 67
- 239000012190 activator Substances 0.000 title claims description 32
- 239000004480 active ingredient Substances 0.000 claims description 51
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims description 45
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 claims description 27
- 239000004202 carbamide Substances 0.000 claims description 24
- SNPLKNRPJHDVJA-ZETCQYMHSA-N D-panthenol Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCCO SNPLKNRPJHDVJA-ZETCQYMHSA-N 0.000 claims description 22
- 235000013305 food Nutrition 0.000 claims description 22
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 claims description 21
- 150000003839 salts Chemical class 0.000 claims description 20
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 claims description 18
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 18
- 235000019155 vitamin A Nutrition 0.000 claims description 18
- 239000011719 vitamin A Substances 0.000 claims description 18
- 229940045997 vitamin a Drugs 0.000 claims description 18
- 229930003799 tocopherol Natural products 0.000 claims description 16
- 229960001295 tocopherol Drugs 0.000 claims description 16
- 235000010384 tocopherol Nutrition 0.000 claims description 16
- 239000011732 tocopherol Substances 0.000 claims description 16
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 claims description 16
- SLXKOJJOQWFEFD-UHFFFAOYSA-N 6-aminohexanoic acid Chemical compound NCCCCCC(O)=O SLXKOJJOQWFEFD-UHFFFAOYSA-N 0.000 claims description 15
- 229960002684 aminocaproic acid Drugs 0.000 claims description 15
- 229920001499 Heparinoid Polymers 0.000 claims description 14
- 239000002554 heparinoid Substances 0.000 claims description 14
- 229940025770 heparinoids Drugs 0.000 claims description 14
- 239000002537 cosmetic Substances 0.000 claims description 11
- 229960004949 glycyrrhizic acid Drugs 0.000 claims description 10
- 235000019410 glycyrrhizin Nutrition 0.000 claims description 10
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 claims description 10
- VTAJIXDZFCRWBR-UHFFFAOYSA-N Licoricesaponin B2 Natural products C1C(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2)C(O)=O)C)(C)CC2)(C)C2C(C)(C)CC1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O VTAJIXDZFCRWBR-UHFFFAOYSA-N 0.000 claims description 8
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 claims description 8
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 claims description 8
- 239000001685 glycyrrhizic acid Substances 0.000 claims description 8
- 229940045136 urea Drugs 0.000 claims description 8
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims description 6
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 claims description 5
- BIVBRWYINDPWKA-VLQRKCJKSA-L Glycyrrhizinate dipotassium Chemical compound [K+].[K+].O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@H]1CC[C@]2(C)[C@H]3C(=O)C=C4[C@@H]5C[C@](C)(CC[C@@]5(CC[C@@]4(C)[C@]3(C)CC[C@H]2C1(C)C)C)C(O)=O)C([O-])=O)[C@@H]1O[C@H](C([O-])=O)[C@@H](O)[C@H](O)[C@H]1O BIVBRWYINDPWKA-VLQRKCJKSA-L 0.000 claims description 5
- 229940101029 dipotassium glycyrrhizinate Drugs 0.000 claims description 5
- 150000002148 esters Chemical class 0.000 claims description 5
- 229940042585 tocopherol acetate Drugs 0.000 claims description 5
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims description 3
- 150000005690 diesters Chemical class 0.000 claims description 3
- 239000000203 mixture Substances 0.000 claims description 2
- 150000001732 carboxylic acid derivatives Chemical class 0.000 claims 2
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 claims 1
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 claims 1
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 claims 1
- 208000017442 Retinal disease Diseases 0.000 claims 1
- 230000003712 anti-aging effect Effects 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 229950006780 n-acetylglucosamine Drugs 0.000 claims 1
- 229960004838 phosphoric acid Drugs 0.000 claims 1
- 230000019612 pigmentation Effects 0.000 claims 1
- 235000013877 carbamide Nutrition 0.000 description 21
- 230000000694 effects Effects 0.000 description 16
- 201000010099 disease Diseases 0.000 description 15
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 15
- 239000003814 drug Substances 0.000 description 12
- 208000024891 symptom Diseases 0.000 description 12
- DFPAKSUCGFBDDF-ZQBYOMGUSA-N [14c]-nicotinamide Chemical compound N[14C](=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-ZQBYOMGUSA-N 0.000 description 10
- 229940079593 drug Drugs 0.000 description 8
- -1 alkali metal salts Chemical class 0.000 description 7
- 239000000825 pharmaceutical preparation Substances 0.000 description 7
- 229940127557 pharmaceutical product Drugs 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 6
- 239000000284 extract Substances 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 230000003213 activating effect Effects 0.000 description 5
- 230000004913 activation Effects 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 208000023504 respiratory system disease Diseases 0.000 description 4
- 235000002639 sodium chloride Nutrition 0.000 description 4
- 239000012085 test solution Substances 0.000 description 4
- 208000035473 Communicable disease Diseases 0.000 description 3
- 208000029578 Muscle disease Diseases 0.000 description 3
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 235000013361 beverage Nutrition 0.000 description 3
- 150000001735 carboxylic acids Chemical class 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 208000030533 eye disease Diseases 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 208000026278 immune system disease Diseases 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 239000000411 inducer Substances 0.000 description 3
- 208000027866 inflammatory disease Diseases 0.000 description 3
- 235000015110 jellies Nutrition 0.000 description 3
- 208000017169 kidney disease Diseases 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 208000012268 mitochondrial disease Diseases 0.000 description 3
- 201000000585 muscular atrophy Diseases 0.000 description 3
- 230000004770 neurodegeneration Effects 0.000 description 3
- 208000015122 neurodegenerative disease Diseases 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- 239000002674 ointment Substances 0.000 description 3
- 229960003471 retinol Drugs 0.000 description 3
- 235000020944 retinol Nutrition 0.000 description 3
- 239000011607 retinol Substances 0.000 description 3
- 210000003491 skin Anatomy 0.000 description 3
- 230000009759 skin aging Effects 0.000 description 3
- 150000003611 tocopherol derivatives Chemical class 0.000 description 3
- 208000011990 Corticobasal Degeneration Diseases 0.000 description 2
- 206010067889 Dementia with Lewy bodies Diseases 0.000 description 2
- 229920002683 Glycosaminoglycan Polymers 0.000 description 2
- 208000030836 Hashimoto thyroiditis Diseases 0.000 description 2
- 201000002832 Lewy body dementia Diseases 0.000 description 2
- 201000009035 MERRF syndrome Diseases 0.000 description 2
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 2
- 206010058799 Mitochondrial encephalomyopathy Diseases 0.000 description 2
- 208000001089 Multiple system atrophy Diseases 0.000 description 2
- 206010028289 Muscle atrophy Diseases 0.000 description 2
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 2
- VYGQUTWHTHXGQB-FFHKNEKCSA-N Retinol Palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C VYGQUTWHTHXGQB-FFHKNEKCSA-N 0.000 description 2
- 229910052783 alkali metal Inorganic materials 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 239000007902 hard capsule Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 201000011548 mitochondrial DNA depletion syndrome 4b Diseases 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 159000000001 potassium salts Chemical class 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 201000002212 progressive supranuclear palsy Diseases 0.000 description 2
- MMXZSJMASHPLLR-UHFFFAOYSA-N pyrroloquinoline quinone Chemical compound C12=C(C(O)=O)C=C(C(O)=O)N=C2C(=O)C(=O)C2=C1NC(C(=O)O)=C2 MMXZSJMASHPLLR-UHFFFAOYSA-N 0.000 description 2
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 2
- 229960002930 sirolimus Drugs 0.000 description 2
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 2
- 159000000000 sodium salts Chemical class 0.000 description 2
- 239000007901 soft capsule Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 1
- 208000022309 Alcoholic Liver disease Diseases 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 206010003591 Ataxia Diseases 0.000 description 1
- 208000023328 Basedow disease Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 206010048962 Brain oedema Diseases 0.000 description 1
- 206010006895 Cachexia Diseases 0.000 description 1
- 229920002567 Chondroitin Polymers 0.000 description 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 208000020406 Creutzfeldt Jacob disease Diseases 0.000 description 1
- 208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 description 1
- 208000010859 Creutzfeldt-Jakob disease Diseases 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 201000003883 Cystic fibrosis Diseases 0.000 description 1
- 235000004866 D-panthenol Nutrition 0.000 description 1
- 239000011703 D-panthenol Substances 0.000 description 1
- 206010011878 Deafness Diseases 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- 201000010374 Down Syndrome Diseases 0.000 description 1
- 208000003556 Dry Eye Syndromes Diseases 0.000 description 1
- 206010013774 Dry eye Diseases 0.000 description 1
- 208000004930 Fatty Liver Diseases 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 208000024869 Goodpasture syndrome Diseases 0.000 description 1
- 208000015023 Graves' disease Diseases 0.000 description 1
- 208000001204 Hashimoto Disease Diseases 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 206010019668 Hepatic fibrosis Diseases 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- 208000032087 Hereditary Leber Optic Atrophy Diseases 0.000 description 1
- 208000023105 Huntington disease Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 description 1
- 201000000639 Leber hereditary optic neuropathy Diseases 0.000 description 1
- 208000006136 Leigh Disease Diseases 0.000 description 1
- 208000017507 Leigh syndrome Diseases 0.000 description 1
- 208000033868 Lysosomal disease Diseases 0.000 description 1
- 208000015439 Lysosomal storage disease Diseases 0.000 description 1
- 208000035177 MELAS Diseases 0.000 description 1
- 208000001145 Metabolic Syndrome Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000010428 Muscle Weakness Diseases 0.000 description 1
- 208000021642 Muscular disease Diseases 0.000 description 1
- 206010028372 Muscular weakness Diseases 0.000 description 1
- 241000187479 Mycobacterium tuberculosis Species 0.000 description 1
- 201000009623 Myopathy Diseases 0.000 description 1
- 208000002537 Neuronal Ceroid-Lipofuscinoses Diseases 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 206010033645 Pancreatitis Diseases 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 208000025535 REM sleep behavior disease Diseases 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 208000007014 Retinitis pigmentosa Diseases 0.000 description 1
- 241000607768 Shigella Species 0.000 description 1
- 208000021386 Sjogren Syndrome Diseases 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 241001505901 Streptococcus sp. 'group A' Species 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 201000009594 Systemic Scleroderma Diseases 0.000 description 1
- 206010042953 Systemic sclerosis Diseases 0.000 description 1
- 241001122767 Theaceae Species 0.000 description 1
- 206010044688 Trisomy 21 Diseases 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 206010064930 age-related macular degeneration Diseases 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 230000001668 ameliorated effect Effects 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 210000004961 autolysosome Anatomy 0.000 description 1
- 210000004957 autophagosome Anatomy 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 208000006752 brain edema Diseases 0.000 description 1
- 201000009267 bronchiectasis Diseases 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000007910 chewable tablet Substances 0.000 description 1
- DLGJWSVWTWEWBJ-HGGSSLSASA-N chondroitin Chemical compound CC(O)=N[C@@H]1[C@H](O)O[C@H](CO)[C@H](O)[C@@H]1OC1[C@H](O)[C@H](O)C=C(C(O)=O)O1 DLGJWSVWTWEWBJ-HGGSSLSASA-N 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- YNNUSGIPVFPVBX-NHCUHLMSSA-N clemastine Chemical compound CN1CCC[C@@H]1CCO[C@@](C)(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 YNNUSGIPVFPVBX-NHCUHLMSSA-N 0.000 description 1
- 229960002881 clemastine Drugs 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 231100000895 deafness Toxicity 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 210000005175 epidermal keratinocyte Anatomy 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 235000015203 fruit juice Nutrition 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 206010061989 glomerulosclerosis Diseases 0.000 description 1
- 208000016354 hearing loss disease Diseases 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 238000010191 image analysis Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000001965 increasing effect Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 208000036971 interstitial lung disease 2 Diseases 0.000 description 1
- 230000010039 intracellular degradation Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 208000006443 lactic acidosis Diseases 0.000 description 1
- 239000000865 liniment Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000003712 lysosome Anatomy 0.000 description 1
- 230000001868 lysosomic effect Effects 0.000 description 1
- 208000002780 macular degeneration Diseases 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- BUGYDGFZZOZRHP-UHFFFAOYSA-N memantine Chemical compound C1C(C2)CC3(C)CC1(C)CC2(N)C3 BUGYDGFZZOZRHP-UHFFFAOYSA-N 0.000 description 1
- 229960004640 memantine Drugs 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 230000020763 muscle atrophy Effects 0.000 description 1
- 201000006938 muscular dystrophy Diseases 0.000 description 1
- 206010028417 myasthenia gravis Diseases 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- 201000008051 neuronal ceroid lipofuscinosis Diseases 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 239000011570 nicotinamide Substances 0.000 description 1
- 229960003966 nicotinamide Drugs 0.000 description 1
- 235000005152 nicotinamide Nutrition 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 description 1
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 229960000342 retinol acetate Drugs 0.000 description 1
- 150000004609 retinol derivatives Chemical class 0.000 description 1
- QGNJRVVDBSJHIZ-QHLGVNSISA-N retinyl acetate Chemical compound CC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C QGNJRVVDBSJHIZ-QHLGVNSISA-N 0.000 description 1
- 235000019173 retinyl acetate Nutrition 0.000 description 1
- 239000011770 retinyl acetate Substances 0.000 description 1
- 229940108325 retinyl palmitate Drugs 0.000 description 1
- 235000019172 retinyl palmitate Nutrition 0.000 description 1
- 239000011769 retinyl palmitate Substances 0.000 description 1
- 208000001076 sarcopenia Diseases 0.000 description 1
- 150000004671 saturated fatty acids Chemical class 0.000 description 1
- 201000009890 sinusitis Diseases 0.000 description 1
- 230000007958 sleep Effects 0.000 description 1
- 235000015096 spirit Nutrition 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000011708 vitamin B3 Substances 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
Classifications
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Cosmetics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Description
項1. ヘパリン類似物質、グリチルリチン酸及びその塩、トコフェロール及びその誘導体、εアミノカプロン酸及びその塩、ニコチン酸アミド、尿素、パントテニルアルコール、並びにビタミンAよりなる群から選択される少なくとも1種を有効成分として含む、オートファジー活性化剤。
項2. 前記有効成分が、ヘパリン類似物質、グリチルリチン酸ジカリウム、トコフェロール酢酸エステル、εアミノカプロン酸、ニコチン酸アミド、尿素、パントテニルアルコール、及びビタミンAよりなる群から選択される少なくとも1種である、項1に記載のオートファジー活性化剤。
項3. 飲食品、医薬品、又は化粧料である、項1又は2に記載のオートファジー活性化剤。
ヘパリン類似物質は、コンドロイチン多硫酸等の多硫酸化ムコ多糖であり、保湿作用や血流量増加作用等を有することが知られている公知の薬剤である。本発明で使用されるヘパリン類似物質の由来については、特に制限されないが、例えば、ムコ多糖類を多硫酸化することにより得られたもの、食用獣の組織(例えば、ウシの気管軟骨を含む肺臓)から抽出したもの等が挙げられる。本発明では、日本薬局方外医薬品規格に収戴されているヘパリン類似物質が好適に使用される。
本発明のオートファジー活性化剤の剤型については、特に限定されず、固体状、半固体状、又は液体状のいずれであってもよい。
本発明のオートファジー活性化剤は、生体内でオートファジーの活性を向上させる用途に使用される。
Claims (3)
- ヘパリン類似物質、グリチルリチン酸及びその塩、トコフェロール、トコフェロールとカルボン酸とのエステル体、トコフェロールとリン酸とのジエステル体、εアミノカプロン酸及びその塩、尿素、パントテニルアルコール、並びにビタミンAよりなる群から選択される少なくとも1種を有効成分として含む、オートファジー活性化剤
(但し、以下の(1)~(4)のいずれかに該当する場合を除く:
(1)N-アセチルグルコサミンを含む場合
(2)有効成分として、ヘパリン類似物質、尿素、及びトコフェロール、トコフェロールとカルボン酸とのエステル体、トコフェロールとリン酸とのジエステル体よりなる群から選択される少なくとも1種を使用し、且つ皮膚の抗老化用途に使用される場合
(3)有効成分として、εアミノカプロン酸及びその塩よりなる群から選択される少なくとも1種を使用し且つ、網膜疾患の治療用途に使用される場合
(4)有効成分として、パントテニルアルコールを使用し、且つ色素沈着抑制用途に使用される場合)。 - 前記有効成分が、ヘパリン類似物質、グリチルリチン酸ジカリウム、トコフェロール酢酸エステル、εアミノカプロン酸、尿素、パントテニルアルコール、及びビタミンAよりなる群から選択される少なくとも1種である、請求項1に記載のオートファジー活性化剤。
- 飲食品、医薬品、又は化粧料である、請求項1又は2に記載のオートファジー活性化剤。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2020080581A JP7505912B2 (ja) | 2020-04-30 | 2020-04-30 | オートファジー活性化剤 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2020080581A JP7505912B2 (ja) | 2020-04-30 | 2020-04-30 | オートファジー活性化剤 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2021172641A JP2021172641A (ja) | 2021-11-01 |
JP7505912B2 true JP7505912B2 (ja) | 2024-06-25 |
Family
ID=78279565
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2020080581A Active JP7505912B2 (ja) | 2020-04-30 | 2020-04-30 | オートファジー活性化剤 |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP7505912B2 (ja) |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2005060234A (ja) | 2003-08-08 | 2005-03-10 | Rohto Pharmaceut Co Ltd | 皮膚外用剤 |
US20120015901A1 (en) | 2009-01-14 | 2012-01-19 | Katholieke Universiteit Leuven, K.U.Leuven R&D | Methods and preparations for protecting critically ill patients |
JP2012041302A (ja) | 2010-08-20 | 2012-03-01 | Kracie Home Products Ltd | 皮膚化粧料 |
JP2020180050A (ja) | 2019-04-23 | 2020-11-05 | ポーラ化成工業株式会社 | メラノサイト活性化因子の産生抑制剤 |
JP2022548071A (ja) | 2019-09-13 | 2022-11-16 | アメリカ合衆国 | 網膜変性を治療するための新薬の開発につながる標的 |
-
2020
- 2020-04-30 JP JP2020080581A patent/JP7505912B2/ja active Active
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2005060234A (ja) | 2003-08-08 | 2005-03-10 | Rohto Pharmaceut Co Ltd | 皮膚外用剤 |
US20120015901A1 (en) | 2009-01-14 | 2012-01-19 | Katholieke Universiteit Leuven, K.U.Leuven R&D | Methods and preparations for protecting critically ill patients |
JP2012041302A (ja) | 2010-08-20 | 2012-03-01 | Kracie Home Products Ltd | 皮膚化粧料 |
JP2020180050A (ja) | 2019-04-23 | 2020-11-05 | ポーラ化成工業株式会社 | メラノサイト活性化因子の産生抑制剤 |
JP2022548071A (ja) | 2019-09-13 | 2022-11-16 | アメリカ合衆国 | 網膜変性を治療するための新薬の開発につながる標的 |
Also Published As
Publication number | Publication date |
---|---|
JP2021172641A (ja) | 2021-11-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11166972B2 (en) | Compositions comprising nicotinamide riboside and a urolithin | |
EP2036552B1 (en) | Senescence inhibitor | |
TWI402069B (zh) | 含斛黃素組合物 | |
JP6863886B2 (ja) | インフラマソーム活性化抑制剤 | |
JP2007126455A (ja) | 脳機能障害の改善剤 | |
CA2982645C (en) | Composition for suppressing muscular fatty change | |
WO2017135466A1 (ja) | キサントフィルとヒシ属植物の加工物を含有する組成物 | |
WO2018164221A1 (ja) | 筋線維化抑制用組成物 | |
JP2016506381A (ja) | シクロデキストリンを含むカテキン生体利用率増進剤 | |
JP5922863B2 (ja) | 運動機能改善剤 | |
JP6096943B2 (ja) | 飲食品組成物 | |
JPWO2015015816A1 (ja) | 繊維芽細胞賦活剤 | |
JP7505912B2 (ja) | オートファジー活性化剤 | |
JP6902329B2 (ja) | 皮脂腺細胞の活性化の抑制剤 | |
JP5619752B2 (ja) | パンドラチン誘導体またはボエセンベルギアパンドラタ抽出物の新規な用途 | |
KR102037719B1 (ko) | 이오논을 유효성분으로 함유하는 항스트레스제, 항우울제 또는 항불안제 조성물 | |
KR101830395B1 (ko) | 스쿠알렌을 함유하는 근기능 향상 및 근육 손상 예방용 조성물 | |
JP6225199B2 (ja) | 運動機能改善剤 | |
JP2007015970A (ja) | ビタミンa類安定化製剤 | |
WO2015015815A1 (ja) | 繊維芽細胞賦活剤 | |
CN104177318A (zh) | L-抗坏血酸-6-(10-羟基-2-癸烯酸)酯或其衍生物以及它们的应用 | |
WO2009110495A1 (ja) | インスリン様成長因子-1分泌促進剤およびそれを含む飲食品 | |
JP7503564B2 (ja) | Tgr5活性化用組成物 | |
US11197878B2 (en) | Anti-inflammatory composition including novel quercetin-based compound | |
JP6091067B2 (ja) | 細胞賦活剤およびその用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20221219 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20240109 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20240311 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240508 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20240521 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20240613 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 7505912 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |